A $1.1 billion market in 2027, with a CAGR of 8%

The global Automated External Defibrillator (AED) market is expected to grow at a CAGR of over 8% from 2021 to 2026. It is expected to reach over USD 1.4 billion by 2026, from just over USD 1.1 billion in 2020.

Bedfordshire, UK, April 19, 2022 (GLOBE NEWSWIRE) — Accuracy Consultancy, the market research and consultancy wing of Improve Digital Consultancy Private Limited, has completed and published the final version of the detailed research report on the Automated External Defibrillator (AED) Market. We have been studying the market for 10 years and here is our 6and edition of the report. It took us about 3 months to complete the research and finally make it available in the market for sale.

Some of our key findings from the research are:

  1. Automated defibrillators are devices that automatically analyze the heart rhythm and if a problem is detected, they react by delivering an electric shock to restore a normal heart rhythm. It has a small size and is easy to use, thanks to which AEDs are connected in many environments (such as hospitals and airports), and play a key role in increasing the number of life-saving defibrillation opportunities.

  2. The FDA does not intend to enforce compliance with the February 3, 2020 deadline for required AED accessories until February 3, 2022 to allow healthcare facilities time to transition to FDA-approved AEDs. FDA. Thus, if a PMA is not filed by February 3, 2022, the manufacturer will have to stop marketing its accessories. This time-to-market includes necessary AED accessories that are labeled for AEDs that are not FDA cleared.

Main market players:

During our research, we studied the major market players globally as well as some prominent local players. We have made a detailed list of all available players that we could find through our research and have included the ones mentioned below in our list:

ST. Jude Medical (Abbott Inc.), Cardiac Science Corporation, Biotronik Se & Co.KG, Medtronic, Inc, Sorin Group, Koninklijke Philips NV, Nihon Kohden Corporation, Zoll Medical Corporation, Physio-Control, Inc, Boston Scientific Corporation and others


News and latest market trends:

  1. Abbott announced that it has received CE Mark for the new Gallant™ Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds), bringing the most advanced cardiac rhythm management capabilities along with a new set of benefit to people in Europe with abnormal heart rhythms and heart failure.

  2. Automated portable defibrillators are portable devices capable of delivering an electric shock to the heart to prevent sudden cardiac death (SDC).

  3. Boston Scientific Corporation has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and efficacy of the mCRM™ Modular Therapy System. The mCRM System consists of two cardiac rhythm management (CRM) devices intended to work together to coordinate therapy: the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Modular Pacing System ( MPS), which is designed to be the first leadless pacemaker capable of providing both bradycardia pacing assistance and antitachycardia pacing (ATP).

Recent market developments:

  1. ZOLL Medical Corporation, an Asahi Kasei Group company that manufactures medical devices and related software solutions, has confirmed that it has completed the previously announced acquisition of Cardiac Science® Corporation, a leading provider of automated external defibrillators (AEDs), related services and accessories.

  2. Royal Philips, a global health technology leader, announced that the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) has granted Premarket Approval (PMA) for the company’s HeartStart FR3. [1] and HeartStart FRx [2] automated external defibrillators (AEDs) and their supporting accessories, including batteries and electrodes.

  3. Boston Scientific Corporation announced the launch and first implant in the United States of its extended life (EL) line of implantable cardioverter defibrillators (ICDs), including the DYNAGEN™ EL and INOGEN™ EL device models. The first EL ICD was implanted at the University of Pittsburgh Medical Center (UPMC)

  4. ZOLL Medical Corporation (ZOLL), an Asahi Kasei Company, has acquired Respicardia, Inc. (Respicardia), an American medical device company that manufactures and sells the remedē® System, an implantable neurostimulatory device for the treatment of central apnea sleep (ACS) . The acquisition process was completed on April 9, 2021 (US Eastern Time).

Report scope and segmentation:



base year


Historical data


Forecast period


Regional scope

Asia-Pacific, North America, Latin America, Europe, Middle East and Africa

By type

Semi-automated external defibrillator
Fully automated external defibrillator

Per deployment

Hospital Fire Fighting
Public access



Scope of customization

15% free personalization

delivery format

PDF and Excel by e-mail

Rebate request here:


Regional analysis:

  1. – North America accounted for the major market share of 39% in 2021 due to growing geriatric population, technological advancements, key companies in the market, and new product launches. According to the Centers for Disease Control and Prevention report released in September 2021, approximately 6.59,000 people in the United States die each year from heart disease and approximately 8.05,000 people have a heart attack each year. The increasing frequency of heart attacks in the United States increases the expansion of the market. Huge healthcare business and adoption of innovative healthcare technologies has fueled the growth of the market.

  2. – The US Automated External Defibrillator market is expected to grow over the forecast period owing to the high burden and growing prevalence of cardiovascular diseases, new product launches and emerging number of key market players in the region.

Market segment analysis

  1. – Philips Healthcare offers its customers a wide range of cardiovascular solutions. The company is a pioneer in the development of treatments for sudden cardiac arrest

  2. – Stryker’s Physio-Control Inc. develops, manufactures and sells defibrillators and cardiopulmonary resuscitation assist devices.

  3. – Fully automated external defibrillators are expected to be widely used by a variety of healthcare institutions. The main reason for the growth is the delivery of high amplitude current pulses to restore normal heart function

  4. – Semi-automatic defibrillators, on the other hand, will represent a significant share of the market. The ease of use provided by clear voice prompts is a major factor in the popularity of semi-automatic defibrillators

You can learn more about our report and also request a sample of our report before purchasing by registering at the link below


Recent Publications:-

Clinical Decision Support Systems Market by Product (Standalone CDSS, CPOE Integrated with CDSS, EHR Integrated with CDSS, CDSS Integrated with CPOE and EHR), Application (Drug Interactions, Drug Allergy Alerts, Clinical Reminders, Guidelines clinics, drug dosing support), delivery method (web-based systems, cloud-based, on-premises systems), component (hardware, software, services) and by region (North America, Europe, Asia-Pacific, South America South, Middle East and Africa) Global Trends and Forecasts from 2019 to 2028The global clinical decision support systems market is expected to reach USD 2.44 billion by 2028, from USD 1.20 billion in 2020, growing at a CAGR of 9.3% from 2021 to 2028.

Controlled-Release Drug Delivery Market by Technology Outlook (Wurster Technique, Coacervation, Micro-encapsulation, Implants, Transdermal, Targeted and Other Delivery) and Application (Injectables, Drug-Eluting Stents, Controlled Oral, Transdermal and Ocular Patches) , Infusion Pumps and Metered Metered Dose Inhalers), and Region (North America, Europe, Asia Pacific, Middle East and Africa, and South America), Global Trends and Forecast 2022 to 2029The global controlled release drug delivery market size is expected to grow at a rate of 7.8% CAGR from 2022 to 2029. It is expected to reach over USD 78.41 billion by 2029, from USD 39.88 billion in 2020 .

Healthcare Actuators Market by Actuation (Electric, Pneumatic, Hydraulic), Type (Linear, Rotary) and Region (North America, Europe, Asia-Pacific, Middle East and Africa), Global Trends and Forecast 2022 to 2029Healthcare Actuators Market is expected to reach USD 1,814 Million by 2029 from USD 1,047 Million in 2020; the market is estimated to grow at a CAGR of 6.3% from 2020 to 2029.

Electronic Drug Delivery Systems Market By Product Type (Electronic Infusion Pump & Syringe, Portable Infusion Pump, Electronic Auto-Injectors, Electronic Inhalers & Others), By Application (Diabetes, Asthma & Chronic Lung Disorders, Cardiovascular Disorders) , multiple sclerosis, critically ill patients and others) ) and by region, global trends and forecasts from 2021 to 2028The global electronic drug delivery systems market is expected to grow at a CAGR of 8.1% from 2019 to 2028. It is expected to reach over USD 14.36 million by 2028, from USD 7.50 million in 2019.

CONTACT: Irfan Tamboli +1 (704) 266-3234 | [email protected]

Shirlene J. Manley